Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
Year: 2024
Type: article
Abstract: Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant-eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment-emergent adverse events. In summary, these findings suggest a benefit of D-RVd front-line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients.
Source: British Journal of Haematology
DOI: 10.1111/bjh.19386
Authors: Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Peter M. Voorhees, Saad Z. Usmani, Paul G. Richardson
Institutions: Emory University, Winship Cancer Institute, Icahn School of Medicine at Mount Sinai, University of Chicago Medical Center, OhioHealth, University of North Carolina at Chapel Hill, University of Nebraska Medical Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Kansas Medical Center, University of California, San Francisco, Janssen Scientific Affairs (United States), Levine Cancer Institute, Wake Forest University, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,940
Funders: Amgen, Bristol-Myers Squibb, Pfizer, Sanofi, Gilead Sciences, Alnylam Pharmaceuticals, Celgene, Karyopharm Therapeutics, Array BioPharma, Regeneron Pharmaceuticals, TG Therapeutics, Prothena, BeiGene, Incyte, SkylineDx, Seagen, Genentech, Johnson and Johnson, Takeda Oncology, Pharmacyclics, U.S. National Library of Medicine
OpenAlex ID: W4393010737